Stocks · News reference

Karyopharm Therapeutics Announces Topline Results From Its Phase 3 XPORT-EC-042 Trial Evaluating Selinexor In Adult Patients With TP53 Wild-Type Advanced Or Recurrent Endometrial Cancer; Trial Did Not Meet Its Primary Endpoint Of Progression Free Survival

Jul 30, 2026, 8:17 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 12:54 PMBenzinga Insights
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you
Read original at benzinga
KPTI
SEC EDGARAug 13, 2026, 11:37 AMSEC EDGAR
8-K filing — Karyopharm Therapeutics Inc. (KPTI)
Filed: 2026-08-13 AccNo: 0001193125-26-347897 Size: 535 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
KPTI
BenzingaAug 13, 2026, 11:32 AMBenzinga Newsdesk
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.
Read original at benzinga
KPTI
BenzingaAug 13, 2026, 11:31 AMBenzinga Newsdesk
Karyopharm Therapeutics Q2 EPS $(2.32) Misses $(1.28) Estimate, Sales $33.432M Beat $32.188M Estimate
Read original at benzinga
KPTI